109 related articles for article (PubMed ID: 8866037)
1. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.
Boyd RA; Zegarac EA; Eldon MA; Sedman AJ; Forgue ST
Biopharm Drug Dispos; 1996 Aug; 17(6):459-70. PubMed ID: 8866037
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
Morton TL; Gattermeir DJ; Petersen CA; Day WW; Schumacher RJ
J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730
[TBL] [Abstract][Full Text] [Related]
4. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
6. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of a 7-day 17 beta-estradiol transdermal delivery system: effect of application site and repeated applications on serum concentrations of estradiol and estrone.
Boyd RA; Yang BB; Abel RB; Eldon MA; Sedman AJ; Forgue ST
J Clin Pharmacol; 1996 Nov; 36(11):998-1005. PubMed ID: 8973988
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Thebault JJ; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1997 Jul; 47(7):859-65. PubMed ID: 9272245
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of orally administered estradiol valerate. Results of a single-dose cross-over bioequivalence study in postmenopausal women.
Zimmermann H; Koytchev R; Mayer O; Börner A; Mellinger U; Breitbarth H
Arzneimittelforschung; 1998 Sep; 48(9):941-7. PubMed ID: 9793623
[TBL] [Abstract][Full Text] [Related]
10. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
Rohr UD; Ehrly AM; Kuhl H
Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
[TBL] [Abstract][Full Text] [Related]
12. [Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system].
Schmolling J; Kusche J; van der Ven H; Schander K
Zentralbl Gynakol; 1998; 120(3):121-5. PubMed ID: 9556902
[TBL] [Abstract][Full Text] [Related]
13. [Effect of a 17 beta estradiol gel preparation on hormone levels in menopausal women].
Araya V; Contreras P; Aguirre C; Foradori A
Rev Med Chil; 1995 Sep; 123(9):1116-21. PubMed ID: 8728735
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of estradiol from two transdermal patches.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Mar; 46(3):307-10. PubMed ID: 8901155
[TBL] [Abstract][Full Text] [Related]
16. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of weekly transdermal estradiol controlled delivery system in postmenopausal Chinese.
Chen GS; Zhang MY; Wang Q; Ye JC
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):407-10. PubMed ID: 9863160
[TBL] [Abstract][Full Text] [Related]
18. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
Eugster-Hausmann M; Waitzinger J; Lehnick D
Climacteric; 2010 Jun; 13(3):219-27. PubMed ID: 20423242
[TBL] [Abstract][Full Text] [Related]
19. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women.
Lippert TH; Seeger H; Mueck AO
Horm Metab Res; 1998 Sep; 30(9):598-600. PubMed ID: 9808331
[TBL] [Abstract][Full Text] [Related]
20. The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol.
Ginsburg ES; Walsh BW; Gao X; Gleason RE; Feltmate C; Barbieri RL
J Soc Gynecol Investig; 1995; 2(1):26-9. PubMed ID: 9420845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
